Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Trastuzumab’s Impact in Older Women with HER2+ BC

Clin Breast Cancer; ePub 2016 Aug 1; Cadoo, et al

Older women with small, node-negative, HER2+ breast cancers saw their disease controlled after receiving adjuvant trastuzumab with chemotherapy in a study involving 244 women. Additionally, cardiac event rates were low.

Investigators looked at overall and distant relapse-free survival in women ≥55 years of age treated with (n=128) and without (n=116) trastuzumab. Among the results:

• Even though patients taking trastuzumab had higher-risk tumors, 4-year overall survival was 99% in both groups.

• Distant relapse-free survival was 99% and 97% in the trastuzumab vs no-trastuzumab contingents, respectively.

• 4 women who took trastuzumab developed heart failure, vs 1 in the group who did not take it.

• No cardiac-related deaths occurred.

Citation: Cadoo, K, Morris P, Cowell E, Patil S, Hudis C, McArthur H. Adjuvant chemotherapy and trastuzumab is safe and effective in older women with small, node-negative, HER2-positive early-stage breast cancer. [Published online ahead of print August 1, 2016]. Clin Breast Cancer. doi:10.1016/j.clbc.2016.07.013.